{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:43:27Z","timestamp":1771922607718,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>On December 10, 2014, the Food and Drug Administration (FDA) licensed the 9-valent human papillomavirus vaccine (9vHPV) for prevention of HPV-related cancers and genital warts. This study aimed to summarize and characterize the first decade of post-licensure surveillance reports of 9vHPV submitted to the Vaccine Adverse Event Reporting System (VAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed VAERS reports following 9vHPV administration in the U.S. during December 2014 through December 2024. Disproportionality analysis was conducted using the reporting odds ratio (ROR) to identify potential safety signals. Reports were categorized by sex, age, seriousness, and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The VAERS received 23,499 reports following administration of 9vHPV: 46.7% were from females, 25.7% from males, and 27.6% with unreported sex. Overall, 92.5% of reports were nonserious. Syncope, dizziness, loss of consciousness and pallor were most common AEs among nonserious reports. Headache, dizziness, pain and syncope were commonly reported serious AEs. Disproportionality analysis identified six MedDRA PTs that were disproportionately reported following 9vHPV vaccination: anaphylactic shock, postural orthostatic tachycardia syndrome (POTS), dizziness postural, complex regional pain syndrome (CRPS), premature menopause and acute disseminated encephalomyelitis (ADEM). Deaths (\n                      <jats:italic>N<\/jats:italic>\n                      =\u202f57) were rare and most lacked sufficient medical documentation to establish causality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The safety profile of 9vHPV over its first decade of use remains consistent with pre-licensure data, with most AEs being nonserious and self-limiting. Disproportionality analysis identified potential safety signals warranting further investigation but did not confirm causality. Continuous surveillance is necessary to further evaluate these rare events and ensure the ongoing safety of 9vHPV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1724482","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:33:09Z","timestamp":1768890789000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-licensure safety surveillance of 9-valent human papillomavirus vaccine using the vaccine adverse event reporting system, 2014\u20132024"],"prefix":"10.3389","volume":"14","author":[{"given":"Jie-Hai","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Dongguan Maternal and Child Health Care Hospital","place":["Dongguan, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Dongguan Maternal and Child Health Care Hospital","place":["Dongguan, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Yong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Dongguan Maternal and Child Health Care Hospital","place":["Dongguan, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Ming","family":"Luo","sequence":"additional","affiliation":[{"name":"Dongguan Maternal and Child Health Care Hospital","place":["Dongguan, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Yan","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Dongguan Maternal and Child Health Care Hospital","place":["Dongguan, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"ref1","volume-title":"Approval letter\u2014GARDASIL 9","year":"2014"},{"key":"ref2","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref3","year":""},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/14760584.2017.1383158","article-title":"9-valent human papillomavirus vaccine: a review of the clinical development program","volume":"16","author":"Luxembourg","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e20191791","DOI":"10.1542\/peds.2019-1791","article-title":"Safety of the 9-valent human papillomavirus vaccine","volume":"144","author":"Shimabukuro","year":"2019","journal-title":"Pediatrics"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10286-019-00653-5","article-title":"Human papillomavirus (HPV) vaccine safety concerning POTS, CRPS and related conditions","volume":"30","author":"Blitshteyn","year":"2020","journal-title":"Clin Auton Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"ref8","year":""},{"key":"ref9","year":""},{"key":"ref10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain\u2013Barr\u00e9 syndrome and fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1161\/CIRCULATIONAHA.112.144501","article-title":"Postural tachycardia syndrome (POTS)","volume":"127","author":"Raj","year":"2013","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/eme04050","article-title":"A randomised placebo-controlled phase III multicentre trial: Low-dose intravenous immunoglobulin treatment for long-standing complex regional pain syndrome (LIPS trial)","volume":"4","author":"Goebel","year":"2017","journal-title":"Effic Mech Eval"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/01.AOG.0000451757.51964.98","article-title":"Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women","volume":"124","year":"2014","journal-title":"Obstet Gynecol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1212\/WNL.0000000000002825","article-title":"Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome","volume":"87","author":"Pohl","year":"2016","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1212\/WNL.0b013e31823dc535","article-title":"Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology","volume":"77","author":"Scott","year":"2011","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1212\/WNL.60.8_suppl_3.S8","article-title":"Research criteria for defining patients with CIDP","volume":"60","author":"Sander","year":"2003","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e2022060993","DOI":"10.1542\/peds.2022-060993","article-title":"Ten-year follow-up of 9-valent human papillomavirus vaccine: immunogenicity, effectiveness, and safety","volume":"152","author":"Restrepo","year":"2023","journal-title":"Pediatrics"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.vaccine.2018.02.034","article-title":"Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the vaccine adverse event reporting system (VAERS), 2009-2015","volume":"36","author":"Arana","year":"2018","journal-title":"Vaccine"},{"key":"ref21","first-page":"457","article-title":"Syncope after vaccination--United States, January 2005-July 2007","volume":"57","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40264-016-0456-3","article-title":"Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in VigiBase\u00ae","volume":"40","author":"Chandler","year":"2017","journal-title":"Drug Saf"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2159215","DOI":"10.1080\/21645515.2022.2159215","article-title":"Extended surveillance to assess safety of 9-valent human papillomavirus vaccine","volume":"18","author":"Sundaram","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40264-017-0625-z","article-title":"Safety of human papillomavirus vaccines: an updated review","volume":"41","author":"Phillips","year":"2018","journal-title":"Drug Saf"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/vaccines11010140","article-title":"Risk of premature ovarian insufficiency after human papilloma virus vaccination: a PRISMA systematic review and meta-analysis of current evidence","volume":"11","author":"Torella","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1177\/0883073817718731","article-title":"Human papillomavirus vaccine and postural orthostatic tachycardia syndrome: a review of current literature","volume":"32","author":"Butts","year":"2017","journal-title":"J Child Neurol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1724482\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:37:58Z","timestamp":1771918678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1724482\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":26,"alternative-id":["10.3389\/fpubh.2026.1724482"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1724482","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"article-number":"1724482"}}